General Information of Drug (ID: DM0NTA3)

Drug Name
(4-phenylpiperazin-1-yl)(p-tolyl)methanone Drug Info
Synonyms
(4-Phenyl-piperazin-1-yl)-p-tolyl-methanone; piperazine, a2; Cambridge id 5345452; AC1LF9G0; Oprea1_767331; Oprea1_285639; CHEMBL239457; SCHEMBL10721885; BDBM25773; MolPort-001-016-695; ZINC196133; HMS1676A12; STK020131; AKOS000671240; MCULE-2746904510; BAS 00500757; 4-methylphenyl 4-phenylpiperazinyl ketone; ST50682677; AB00081719-01; 1-[(4-methylphenyl)carbonyl]-4-phenylpiperazine; SR-01000406866; (4-methylphenyl)(4-phenylpiperazin-1-yl)methanone; (4-methylphenyl)-(4-phenylpiperazin-1-yl)methanone
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
749125
CAS Number
CAS 219989-26-1
TTD Drug ID
DM0NTA3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [2]
Pyrazinamide DM4IF32 Meningeal tuberculosis Approved [3]
Ethionamide DM8K3EI Pulmonary tuberculosis 1B10.Z Approved [4]
Prothionamide DMX0EZJ Tuberculosis 1B10-1B1Z Approved [4]
AFN-1720 DM6AJKC Bacterial infection 1A00-1C4Z Phase 2 [5]
MMV00/0053 DMF27BS Malaria 1F40-1F45 Terminated [6]
Nicotinamide-Adenine-Dinucleotide DM9LRKB N. A. N. A. Investigative [7]
Beta-D-Glucose DM5IHYP Discovery agent N.A. Investigative [7]
2-Hexadecynoic acid DMTFIPZ Discovery agent N.A. Investigative [8]
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole DMX681M Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Fatty acid synthetase I (Bact inhA) TTVTX4N INHA_MYCTU Inhibitor [1]

References

1 Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007 Nov 1;15(21):6649-58.
2 Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17.
3 Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7.
4 Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.
5 Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round. PR Newswire Sep. 4, 2013 10:16 PM.
6 SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. IUBMB Life. 2010 Mar;62(3):204-13.
7 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.